Investigational drugs for hyperuricemia.

abstract：INTRODUCTION:The significant proportion of gout patients not reaching serum urate levels below 6.0 mg/dL and the debated pathogenicity of hyperuricemia (HU) itself motivate investigators to develop new drugs to decrease uricemia. AREAS COVERED:This review discusses the drugs considered to be in active development from...

journal_title：Expert opinion on investigational drugs

authors： Pascart T,Richette P

更新日期：2018-05-01 00:00:00

abstract：:Diminished efficacy in terms of clinical relapses and lesion load on magnetic resonance images for patients developing neutralising antibodies (NAbs) to recombinant IFN-beta may be found in multiple sclerosis. NAbs become detectable over the first few years of therapy, disappearing during the treatment course in some ...

journal_title：Expert opinion on investigational drugs

authors： Bagnato F,Pozzilli C

更新日期：2003-07-01 00:00:00

abstract：:Introduction: Neuropathic pain is a chronic condition that significantly affects the quality of life of millions of people globally. Most of the pharmacologic treatments currently in use demonstrate modest efficacy and over half of all patients do not respond to medical management. Hence, there is a need for new, effi...

journal_title：Expert opinion on investigational drugs

authors： Kushnarev M,Pirvulescu IP,Candido KD,Knezevic NN

更新日期：2020-03-01 00:00:00

abstract：INTRODUCTION:Despite the substantial reduction in cardiovascular morbidity and mortality after the management of dyslipidemia with statins, residual risk remains even after achieving low-density lipoprotein cholesterol targets. This residual risk appears to be partly attributed to low levels of high-density lipoprotein...

journal_title：Expert opinion on investigational drugs

authors： Milonas D,Tziomalos K

更新日期：2019-04-01 00:00:00

abstract：:Histone deacetylase (HDAC) inhibitors are a new class of targeted anticancer agents. Several HDAC inhibitors are in clinical trials and have shown significant activity against a spectrum of both haematological and solid tumours at doses that are well tolerated by patients. HDACs and histone acetyltransferases can, by ...

journal_title：Expert opinion on investigational drugs

authors： Marks PA,Dokmanovic M

更新日期：2005-12-01 00:00:00

abstract：:The association of abnormalities in the cellular and humoral immune system with various autoimmune diseases provides the rationale for apheresis technologies. While plasmapheresis or plasma exchange is limited by its non-selective removal of all plasma components, modern apheresis techniques aim to provide more specif...

journal_title：Expert opinion on investigational drugs

authors： Braun N,Bosch T

更新日期：2000-09-01 00:00:00

abstract：:Argatroban, a synthetic peptidomimetic antithrombin agent, is the first clinical anticoagulant solely to target thrombin. For some time, this drug has been used in Japan for the management of thromboembolic disorders. Recently, it has been approved in Japan for use in thrombotic and ischaemic stroke. Despite a large n...

journal_title：Expert opinion on investigational drugs

authors： Jeske W,Walenga JM,Lewis BE,Fareed J

更新日期：1999-05-01 00:00:00

abstract：INTRODUCTION:Soft tissue sarcomas (STS) are a rare and difficult to treat malignancy. Efforts to utilize targeted therapy have been ongoing for the last decade and have resulted in the approval of pazopanib for treatment of advanced disease. Although several other agents have been investigated, the inability to predict...

journal_title：Expert opinion on investigational drugs

authors： Mohindra N,Agulnik M

更新日期：2015-01-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:The evolution of targeted therapies is dependent upon identification of cellular moieties that can be pharmacologically modulated. As one such example, the serine-threonine kinase Akt was identified nearly two decades ago. Since then, its role in mediating multiple signaling cascades (ultimately...

journal_title：Expert opinion on investigational drugs

authors： Pal SK,Reckamp K,Yu H,Figlin RA

更新日期：2010-11-01 00:00:00

abstract：:Bromocriptine, a potent dopamine D(2) receptor agonist, has been shown to reduce insulin resistance, glucose intolerance and hyperlipidaemia in both numerous animal studies and in Phase II studies. Bromocriptine has been used worldwide for over 20 years to treat Parkinson's disease, macroprolactinoma and other disorde...

journal_title：Expert opinion on investigational drugs

authors： Cincotta AH,Meier AH,Cincotta M Jr

更新日期：1999-10-01 00:00:00

abstract：INTRODUCTION:Since the discovery of the activating V617F mutation in Janus kinase 2 (JAK2), a number of pharmacologic inhibitors of JAK2 have entered clinical trials for patients with myelofibrosis. However, ruxolitinib, approved in 2011, remains the only one currently available for treatment of myelofibrosis, with man...

journal_title：Expert opinion on investigational drugs

authors： Bose P,Abou Zahr A,Verstovsek S

更新日期：2017-06-01 00:00:00

abstract：INTRODUCTION:Diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) are the two complications of diabetes that cause visual loss and blindness. Laser photo-coagulation in the past was used to prevent progression of disease to these advanced stages. Advances in pathophysiologic understanding of DME an...

journal_title：Expert opinion on investigational drugs

authors： Tolentino MS,Tolentino AJ,Tolentino MJ

更新日期：2016-09-01 00:00:00

abstract：:Recent advances in the treatment and management of haematological malignancies are due in large part to an improved understanding of the basic biology that drives tumour cell growth and survival. This improved understanding has led to the clinical study and approval of a number of different targeted agents across a nu...

journal_title：Expert opinion on investigational drugs

authors： Haas M,Lonial S

更新日期：2005-09-01 00:00:00

abstract：INTRODUCTION:In asthma, most commonly, 'conventional' anti-inflammatory medications represented by inhaled corticosteroids and leukotriene inhibitors are effective. In some patients however additional inhibition of the airways inflammation is necessary. Such compounds might be molecules inhibiting specifically certain ...

journal_title：Expert opinion on investigational drugs

authors： Antoniu SA

更新日期：2016-10-01 00:00:00

abstract：BACKGROUND:Clusterin is a stress-induced cytoprotective chaperone protein, regulated by HSF1, and functions similarly to a small heat-shock protein. Clusterin is expressed in a variety of cancers and associated with broad-spectrum treatment resistance. Custirsen (OGX-011) is a 2'-methoxyethyl modified phosphorothioate ...

journal_title：Expert opinion on investigational drugs

authors： Chi KN,Zoubeidi A,Gleave ME

更新日期：2008-12-01 00:00:00

abstract：:Asthma is a serious world health problem characterised by a chronic inflammatory disorder of the airways. Asthma attacks, or exacerbations, are episodic but airway inflammation is chronically present. Thus, this disorder requires long-term management. The goals of asthma management include prevention steps for long-te...

journal_title：Expert opinion on investigational drugs

authors： Centanni S,Santus P

更新日期：2002-01-01 00:00:00

abstract：:Introduction: Osteoarthritis (OA) is the most common form of arthritis. Knee OA is associated with joint pain, activity limitation, physical disability, reduced health-related quality of life, and increased mortality. To date, all pharmacologic treatments for OA are directed toward pain management. Lorecivivint (LOR) ...

journal_title：Expert opinion on investigational drugs

authors： Sabha M,Siaton BC,Hochberg MC

更新日期：2020-12-01 00:00:00

abstract：:Cyclin-dependent protein kinases (CDKs) are key regulators of the cell division cycle, whose various checkpoints proliferating cells must traverse. Since CDK deregulation, either through direct or indirect means, is found in most cancer cells, pharmacological CDK inhibition has become an attractive strategy towards me...

journal_title：Expert opinion on investigational drugs

authors： Fischer PM,Gianella-Borradori A

更新日期：2003-06-01 00:00:00

abstract：:Telomerase is a holoenzyme responsible for the maintenance of telomeres, the protein-nucleic acid complexes at the ends of eukaryotic chromosomes that serve to maintain chromosomal stability and integrity. Telomerase activity is essential for the sustained proliferation of most immortal cells, including cancer cells. ...

journal_title：Expert opinion on investigational drugs

authors： Perry PJ,Arnold JR,Jenkins TC

更新日期：2001-12-01 00:00:00

abstract：:It is now widely accepted that the renin-angiotensin system (RAS) not only contributes to pathological mechanisms involved, e.g. in hypertension or hypertensive and diabetic end-organ damage, but also harbors a "protective arm" represented mainly by two receptors, the AT2 (angiotensin type 2) receptor and the Mas rece...

journal_title：Expert opinion on investigational drugs

authors： Steckelings UM,Unger T

更新日期：2012-06-01 00:00:00

abstract：:Leukotriene B(4) (LTB(4)) is a lipid inflammatory mediator derived from membrane phospholipids by the sequential actions of cytosolic phospholipase A2 (PLA2), 5-lipoxygenase (5-LO) and leukotriene A(4) (LTA(4)) hydrolase. Several inflammatory diseases, including asthma, chronic obstructive pulmonary disease, arthritis...

journal_title：Expert opinion on investigational drugs

authors： Hicks A,Monkarsh SP,Hoffman AF,Goodnow R Jr

更新日期：2007-12-01 00:00:00

abstract：INTRODUCTION:The addition of monoclonal antibody (mAb) epidermal growth factor receptor (EGFR) inhibitors to classic chemotherapy doublet backbones has improved survival of metastatic colorectal cancer (mCRC). However, the role of triple-drug chemotherapy regimens in combination with an anti-EGFR mAb inhibitor is not y...

journal_title：Expert opinion on investigational drugs

authors： Matos I,Noguerido A,Ros J,Mulet N,Argilés G,Elez É,Tabernero J

更新日期：2019-05-01 00:00:00

abstract：:The management of acute myocardial infarction (AMI) has changed dramatically over the last two decades, with the addition of fibrinolytic agents and primary coronary intervention (PCI). The more recent development of the glycoprotein (GP) IIb/IIIa antagonists, a new class of potent antiplatelet drugs, has the potentia...

journal_title：Expert opinion on investigational drugs

authors： Ferguson JJ,Vaisman D

更新日期：2001-11-01 00:00:00

abstract：:Human cytomegalovirus (HCMV) is the most common viral opportunistic infection in patients suffering with acquired immunodeficiency virus (AIDS). HCMV is a systemic infection that may infect several sites in the body, including the retina, gastrointestinal tract, lungs, liver, and central nervous system. Retinitis is t...

journal_title：Expert opinion on investigational drugs

authors： Temsamani J,Pari GS,Guinot P

更新日期：1997-09-01 00:00:00

abstract：BACKGROUND:Today, propofol or 2,6-diisopropylphenol is the anesthetic mainly used for monitored anesthetic care sedation and during intravenous anesthesia. The formulation, a lipid macroemulsion, shows several disadvantages. Therefore, during the past years considerable scientific effort has been undertaken to find eit...

journal_title：Expert opinion on investigational drugs

authors： Fechner J,Ihmsen H,Jeleazcov C,Schüttler J

更新日期：2009-10-01 00:00:00

abstract：:Chronic hepatitis B virus (HBV) infection is a major health problem that is responsible for < or = 1 million deaths and 500,000 cases of hepatocellular carcinoma worldwide each year. Drugs that are currently approved by the FDA for the treatment of chronic HBV consist of two groups: the immunomodulators, such as conve...

journal_title：Expert opinion on investigational drugs

authors： Hui CK,Lau GK

更新日期：2005-10-01 00:00:00

abstract：INTRODUCTION:Obinutuzumab is a novel humanized type II glycoengineered anti-CD20 antibody approved for first-line treatment of chronic lymphocytic leukemia (CLL) in combination with chlorambucil and for treatment of rituximab-refractory follicular lymphoma (FL). Areas covered: We describe current preclinical and clinic...

journal_title：Expert opinion on investigational drugs

authors： Klein C,Bacac M,Umana P,Fingerle-Rowson G

更新日期：2017-10-01 00:00:00

abstract：INTRODUCTION:Basal-like breast cancer is characterized by being triple negative and aggressive. Defects in DNA repair is a promising therapeutic target as BRCA alterations are found in 11 to 42% of these tumors, with a frequency varying according to family history and ethnicity. The oral PARP inhibitors exploit this de...

journal_title：Expert opinion on investigational drugs

authors： Robert M,Frenel JS,Gourmelon C,Patsouris A,Augereau P,Campone M

更新日期：2017-06-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Antiangiogenic strategies are affording considerable interest and have become a major milestone in therapeutics of various adult cancers. However, progress has been slow to expand such therapies to patients with pediatric solid malignancies. AREAS COVERED IN THIS REVIEW:This review discusses th...

journal_title：Expert opinion on investigational drugs

authors： Taylor M,Rössler J,Geoerger B,Vassal G,Farace F

更新日期：2010-07-01 00:00:00

abstract：:Two methods of using tumour located enzymes have been described. These are antibody directed enzyme prodrug therapy (ADEPT) and macromolecule directed enzyme prodrug therapy (MDEPT), where the tumour located enzyme converts a non-toxic prodrug into a cytotoxic drug at tumour sites. The alternative use of tumour locate...

journal_title：Expert opinion on investigational drugs

authors： Bagshawe KD,Burke PJ,Knox RJ,Melton RG,Sharma SK

更新日期：1999-02-01 00:00:00